Ticker Hub
IBRX — AI Analysis & Sentiment
4 recent AI-generated analyses for IBRX. Sentiment and confidence insights updated continuously.
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio's ANKTIVA+BCG demonstrated superior efficacy and safety in comparative clinical data, providing a strong competitive advantage in the B...
May 19, 2026EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX
ImmunityBio faces a new class action lawsuit alleging misrepresentation of a key product. This legal overhang, coupled with the company's negative ...
Mar 26, 2026ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
ImmunityBio's ANKTIVA approval in Macau represents a significant step into the Asian market for a core product, enhancing long-term growth prospect...
Mar 20, 2026ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
ImmunityBio’s milestone in NK cell production scalability strengthens its clinical pipeline and positions it for broader applications in cancer tre...
Mar 13, 2026